Borealis Biosciences, a Vancouver-based startup specializing in next-generation RNA medicines for kidney diseases, emerged from stealth with a combined Series A financing totalling US$150 million—approximately C$202 million—supported by founding investor Versant Ventures and Swiss pharma giant Novartis AG. Alongside financing, Novartis will provide strategic research collaboration funding of up to US$100 million, along with an option to acquire two future development-ready programs from Borealis, potentially delivering up to US$750 million in milestone payments. Borealis builds upon the legacy of Chinook Therapeutics, leveraging the same leadership and research team to pursue RNA-based therapeutic innovation targeting unmet needs in renal medicine.